CO6940431A2 - Métodos para preparar análogos nucleotídicos antivirales - Google Patents
Métodos para preparar análogos nucleotídicos antiviralesInfo
- Publication number
- CO6940431A2 CO6940431A2 CO14093468A CO14093468A CO6940431A2 CO 6940431 A2 CO6940431 A2 CO 6940431A2 CO 14093468 A CO14093468 A CO 14093468A CO 14093468 A CO14093468 A CO 14093468A CO 6940431 A2 CO6940431 A2 CO 6940431A2
- Authority
- CO
- Colombia
- Prior art keywords
- methods
- nucleotide analogs
- preparing antiviral
- antiviral nucleotide
- preparing
- Prior art date
Links
- 230000000840 anti-viral effect Effects 0.000 title 1
- 125000003729 nucleotide group Chemical group 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6509—Six-membered rings
- C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161544950P | 2011-10-07 | 2011-10-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6940431A2 true CO6940431A2 (es) | 2014-05-09 |
Family
ID=47297386
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO14093468A CO6940431A2 (es) | 2011-10-07 | 2014-05-02 | Métodos para preparar análogos nucleotídicos antivirales |
Country Status (25)
| Country | Link |
|---|---|
| US (4) | US8664386B2 (es) |
| EP (2) | EP2764002B1 (es) |
| JP (2) | JP6190372B2 (es) |
| KR (3) | KR102139440B1 (es) |
| CN (4) | CN113264959A (es) |
| AR (1) | AR088109A1 (es) |
| AU (1) | AU2012319172B2 (es) |
| BR (1) | BR112014011340A2 (es) |
| CA (2) | CA2850466C (es) |
| CL (1) | CL2014000827A1 (es) |
| CO (1) | CO6940431A2 (es) |
| CR (1) | CR20140204A (es) |
| EA (1) | EA027086B1 (es) |
| EC (1) | ECSP14000074A (es) |
| ES (2) | ES2661705T3 (es) |
| HK (3) | HK1200834A1 (es) |
| IL (1) | IL231879B (es) |
| MX (1) | MX353064B (es) |
| PE (1) | PE20141160A1 (es) |
| PL (1) | PL3333173T3 (es) |
| PT (2) | PT3333173T (es) |
| SI (1) | SI3333173T1 (es) |
| TW (4) | TWI689513B (es) |
| UY (1) | UY34361A (es) |
| WO (1) | WO2013052094A2 (es) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX336627B (es) | 2011-08-16 | 2016-01-26 | Gilead Sciences Inc | Hemifumarato de tenofovir alafenamida. |
| PT3333173T (pt) | 2011-10-07 | 2019-09-10 | Gilead Sciences Inc | Métodos de preparação de análogos de nucleótidos antivirais |
| CN107312039B (zh) | 2012-08-30 | 2019-06-25 | 江苏豪森药业集团有限公司 | 一种替诺福韦前药的制备方法 |
| CA2914381A1 (en) | 2013-06-07 | 2014-12-11 | Cipla Limited | An efficient process for separation of diastereomers of 9-[(r)-2-[[(r,s)-[[(s)-1-(isopropoxycarbonyl)ethyl]amino]-phenoxyphosphinyl] methoxy]propyl]adenine |
| CN104628773B (zh) * | 2013-11-06 | 2018-10-23 | 杭州和泽医药科技有限公司 | (r)-9-[2-(磷酰苯酚基甲氧基)丙基]腺嘌呤的制备方法 |
| WO2015079455A2 (en) * | 2013-11-27 | 2015-06-04 | Laurus Labs Private Limited | A recycling process for preparing tenofovir alafenamide diastereomers |
| EP3077404B1 (en) | 2014-01-14 | 2020-10-07 | Mylan Laboratories Ltd. | Purification of tenofovir alafenamide and its intermediates |
| TWI660965B (zh) | 2014-01-15 | 2019-06-01 | 美商基利科學股份有限公司 | 泰諾福韋之固體形式 |
| WO2015161785A1 (zh) * | 2014-04-21 | 2015-10-29 | 四川海思科制药有限公司 | 氨基磷酸酯类衍生物制备方法及其中间体和中间体的制备方法 |
| CN105518012B (zh) * | 2014-06-25 | 2018-03-02 | 四川海思科制药有限公司 | 一种取代的氨基酸硫酯类化合物、其组合物及应用 |
| CN105399771B (zh) | 2014-07-21 | 2020-11-24 | 江苏豪森药业集团有限公司 | 替诺福韦前药晶型及其制备方法和用途 |
| CN108148094A (zh) * | 2014-11-12 | 2018-06-12 | 四川海思科制药有限公司 | 一种替诺福韦艾拉酚胺富马酸盐晶型c及其制备方法和用途 |
| CN104817593B (zh) * | 2015-04-27 | 2016-11-16 | 广州同隽医药科技有限公司 | 半富马酸替诺福韦艾拉酚胺关键中间体的合成工艺 |
| SI3331891T1 (sl) | 2015-08-05 | 2022-04-29 | Eisai R&D Management Co., Ltd. | Postopek priprave v bistvu diastereomerno čistega fosforodiamidatnega oligomera, fosforodiamidatni oligomer izdelan po takem postopku in farmacevtski sestavek, ki vsebuje tak fosforodiamidatni oligomer |
| TWI616452B (zh) * | 2015-08-26 | 2018-03-01 | Preparation method of nucleoside analog and intermediate thereof | |
| CN105330700A (zh) * | 2015-12-17 | 2016-02-17 | 中国药科大学 | 富马酸替诺福韦艾拉酚胺杂质的制备方法 |
| WO2017118928A1 (en) | 2016-01-06 | 2017-07-13 | Lupin Limited | Process for the separation of diastereomers of tenofovir alafenamide |
| CZ2016156A3 (cs) | 2016-03-17 | 2017-09-27 | Zentiva, K.S. | Způsob přípravy diastereomerně čistého Tenofoviru Alafenamidu nebo jeho solí |
| CN107286190A (zh) * | 2016-04-13 | 2017-10-24 | 刘沛 | 核苷之烃氧基苄基氨基磷酸/膦酸酯衍生物的制备及其医药用途 |
| CN109562113A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的螺环降解决定子体 |
| EP3454856A4 (en) | 2016-05-10 | 2019-12-25 | C4 Therapeutics, Inc. | HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
| WO2017197046A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | C3-carbon linked glutarimide degronimers for target protein degradation |
| CN106565785B (zh) * | 2016-11-09 | 2019-11-12 | 周雨恬 | 一种具有抗hbv/hiv活性的核苷氨基磷酸酯类化合物及其盐和用途 |
| CN106946935B (zh) * | 2017-04-28 | 2020-01-07 | 福建广生堂药业股份有限公司 | 一种非对映异构体核苷衍生物的制备方法 |
| US10590136B2 (en) * | 2017-10-04 | 2020-03-17 | Celgene Corporation | Processes for the preparation of cis-4-[2-{[(3S,4R)-3-fluorooxan-4-yl]amino}-8-(2,4,6-trichloroanilino)-9H-purin-9-yl]-1-methylcyclohexane-1-carboxamide |
| CN109942633B (zh) * | 2017-12-20 | 2021-08-31 | 上海新礼泰药业有限公司 | 替诺福韦艾拉酚胺中间体的制备方法 |
| CN109942632B (zh) * | 2017-12-20 | 2021-08-31 | 上海博志研新药物研究有限公司 | 替诺福韦艾拉酚胺中间体的制备方法 |
| CN110092803A (zh) * | 2018-01-31 | 2019-08-06 | 北京睿创康泰医药研究院有限公司 | 替诺福韦艾拉酚胺富马酸盐工艺杂质的制备及其应用 |
| CN108409788B (zh) * | 2018-03-12 | 2020-05-08 | 科兴生物制药股份有限公司 | 一种富马酸替诺福韦艾拉酚胺的制备方法 |
| CN110305163A (zh) * | 2018-03-27 | 2019-10-08 | 北京济美堂医药研究有限公司 | 替诺福韦艾拉酚胺半富马酸盐的制备方法 |
| CN108467410B (zh) * | 2018-04-09 | 2021-04-09 | 重庆三圣实业股份有限公司 | 一种taf中间体的制备方法及产品和应用 |
| CN108484672A (zh) * | 2018-05-23 | 2018-09-04 | 中国药科大学制药有限公司 | 磷丙替诺福韦的手性拆分方法 |
| CN108822149B (zh) * | 2018-06-01 | 2020-08-11 | 成都苑东生物制药股份有限公司 | 一种富马酸替诺福韦艾拉酚胺关键中间体的制备方法 |
| CN110283208B (zh) * | 2018-06-22 | 2022-07-08 | 南京济群医药科技股份有限公司 | 一种替诺福韦艾拉酚胺的手性拆分方法 |
| CN109081853A (zh) * | 2018-09-03 | 2018-12-25 | 南京正大天晴制药有限公司 | 一种磷丙替诺福韦有关物质的制备方法 |
| CN111484527A (zh) * | 2019-01-25 | 2020-08-04 | 上海清松制药有限公司 | 一种替诺福韦艾拉酚胺中间体的制备方法 |
| CN111943981A (zh) * | 2019-05-14 | 2020-11-17 | 博瑞生物医药泰兴市有限公司 | 一种磷丙替诺福韦的制备方法 |
| CN114409706B (zh) * | 2019-07-01 | 2023-11-28 | 上海医药工业研究院 | 一种苯基氢膦酸酯及其中间体的制备方法 |
| US20220257619A1 (en) | 2019-07-18 | 2022-08-18 | Gilead Sciences, Inc. | Long-acting formulations of tenofovir alafenamide |
| CN112390824B (zh) * | 2019-08-19 | 2022-07-05 | 鲁南制药集团股份有限公司 | 一种替诺福韦艾拉酚胺中间体的制备方法 |
| CN110981911A (zh) * | 2019-10-08 | 2020-04-10 | 浙江车头制药股份有限公司 | 一种替诺福韦艾拉酚胺的制备方法 |
| CN111171076A (zh) * | 2019-12-26 | 2020-05-19 | 合肥启旸生物科技有限公司 | 一种替诺福韦二聚体的制备方法 |
| KR20220156884A (ko) | 2020-03-20 | 2022-11-28 | 길리애드 사이언시즈, 인코포레이티드 | 4'-c-치환된-2-할로-2'-데옥시아데노신 뉴클레오시드의 프로드러그 및 이의 제조 및 사용 방법 |
| KR20210125298A (ko) | 2020-04-08 | 2021-10-18 | 주식회사 파마코스텍 | 테노포비어 알라펜아미드 헤미타르트레이트의 신규한 제조방법 |
| CA3195799A1 (en) | 2020-11-11 | 2022-05-19 | Stephen R. Martin | Methods of identifying hiv patients sensitive to therapy with gp120 cd4 binding site-directed antibodies |
| KR20220141457A (ko) | 2021-04-13 | 2022-10-20 | 경동제약 주식회사 | 신규 결정형의 테노포비어 알라펜아미드 말레산염 및 이를 포함하는 약제학적 조성물 |
| TW202400172A (zh) | 2022-04-06 | 2024-01-01 | 美商基利科學股份有限公司 | 橋聯三環胺甲醯基吡啶酮化合物及其用途 |
| WO2024006982A1 (en) | 2022-07-01 | 2024-01-04 | Gilead Sciences, Inc. | Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection |
| US20240083984A1 (en) | 2022-08-26 | 2024-03-14 | Gilead Sciences, Inc. | Dosing and scheduling regimen for broadly neutralizing antibodies |
| WO2024076915A1 (en) | 2022-10-04 | 2024-04-11 | Gilead Sciences, Inc. | 4'-thionucleoside analogues and their pharmaceutical use |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ536942A (en) * | 2000-07-21 | 2006-03-31 | Gilead Sciences Inc | Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same |
| US20050239054A1 (en) | 2002-04-26 | 2005-10-27 | Arimilli Murty N | Method and compositions for identifying anti-HIV therapeutic compounds |
| US7871991B2 (en) | 2004-07-27 | 2011-01-18 | Gilead Sciences, Inc. | Phosphonate analogs of HIV inhibitor compounds |
| UA97241C2 (uk) * | 2006-03-29 | 2012-01-25 | Гіліад Сайєнсіз, Інк. | Спосіб одержання інгібіторів віл-протеази |
| AU2007269557B2 (en) * | 2006-07-07 | 2013-11-07 | Gilead Sciences, Inc. | Modulators of toll-like receptor 7 |
| NZ573888A (en) * | 2006-07-21 | 2012-02-24 | Gilead Sciences Inc | Aza-peptide protease inhibitors |
| CN101495461A (zh) * | 2006-07-24 | 2009-07-29 | 吉里德科学公司 | 新的hiv逆转录酶抑制剂 |
| US8354421B2 (en) * | 2007-06-29 | 2013-01-15 | Korea Research Insitute Of Chemical Technology | HIV reverse transcriptase inhibitors |
| MX336627B (es) | 2011-08-16 | 2016-01-26 | Gilead Sciences Inc | Hemifumarato de tenofovir alafenamida. |
| PT3333173T (pt) * | 2011-10-07 | 2019-09-10 | Gilead Sciences Inc | Métodos de preparação de análogos de nucleótidos antivirais |
-
2012
- 2012-10-03 PT PT18153951T patent/PT3333173T/pt unknown
- 2012-10-03 PE PE2014000495A patent/PE20141160A1/es not_active Application Discontinuation
- 2012-10-03 EP EP12798029.0A patent/EP2764002B1/en active Active
- 2012-10-03 EP EP18153951.1A patent/EP3333173B1/en active Active
- 2012-10-03 PL PL18153951T patent/PL3333173T3/pl unknown
- 2012-10-03 KR KR1020197019875A patent/KR102139440B1/ko active IP Right Grant
- 2012-10-03 UY UY34361A patent/UY34361A/es not_active Application Discontinuation
- 2012-10-03 CN CN202110408116.9A patent/CN113264959A/zh active Pending
- 2012-10-03 MX MX2014003952A patent/MX353064B/es active IP Right Grant
- 2012-10-03 TW TW106145797A patent/TWI689513B/zh active
- 2012-10-03 TW TW101136508A patent/TWI557133B/zh active
- 2012-10-03 SI SI201231626T patent/SI3333173T1/sl unknown
- 2012-10-03 BR BR112014011340A patent/BR112014011340A2/pt unknown
- 2012-10-03 CN CN202311252160.0A patent/CN117343101A/zh active Pending
- 2012-10-03 JP JP2014534535A patent/JP6190372B2/ja active Active
- 2012-10-03 CN CN201710365515.5A patent/CN107266498B/zh active Active
- 2012-10-03 US US13/573,666 patent/US8664386B2/en active Active
- 2012-10-03 KR KR1020147011619A patent/KR102033802B1/ko active IP Right Grant
- 2012-10-03 PT PT127980290T patent/PT2764002T/pt unknown
- 2012-10-03 EA EA201490753A patent/EA027086B1/ru unknown
- 2012-10-03 CA CA2850466A patent/CA2850466C/en active Active
- 2012-10-03 WO PCT/US2012/000441 patent/WO2013052094A2/en active Application Filing
- 2012-10-03 AR ARP120103681 patent/AR088109A1/es not_active Application Discontinuation
- 2012-10-03 TW TW105126598A patent/TWI613211B/zh active
- 2012-10-03 TW TW108139308A patent/TWI709567B/zh active
- 2012-10-03 ES ES12798029.0T patent/ES2661705T3/es active Active
- 2012-10-03 CA CA3042169A patent/CA3042169C/en active Active
- 2012-10-03 CN CN201280048965.7A patent/CN103842366B/zh active Active
- 2012-10-03 AU AU2012319172A patent/AU2012319172B2/en active Active
- 2012-10-03 KR KR1020207021316A patent/KR20200090975A/ko active Application Filing
- 2012-10-03 ES ES18153951T patent/ES2746859T3/es active Active
-
2014
- 2014-01-14 US US14/154,313 patent/US9029534B2/en active Active
- 2014-04-02 IL IL23187914A patent/IL231879B/en active IP Right Grant
- 2014-04-03 CL CL2014000827A patent/CL2014000827A1/es unknown
- 2014-05-02 CO CO14093468A patent/CO6940431A2/es active IP Right Grant
- 2014-05-05 EC ECIEPI201474A patent/ECSP14000074A/es unknown
- 2014-05-05 CR CR20140204A patent/CR20140204A/es unknown
-
2015
- 2015-02-06 HK HK15101331.9A patent/HK1200834A1/xx unknown
- 2015-02-06 HK HK18114351.4A patent/HK1255222B/zh unknown
- 2015-04-08 US US14/681,955 patent/US9346841B2/en active Active
-
2016
- 2016-04-21 US US15/135,357 patent/US9676804B2/en active Active
-
2017
- 2017-04-19 JP JP2017083047A patent/JP2017160228A/ja not_active Withdrawn
-
2018
- 2018-04-17 HK HK18104995.7A patent/HK1245798A1/zh unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6940431A2 (es) | Métodos para preparar análogos nucleotídicos antivirales | |
| IL252345A0 (en) | Antiviral compounds | |
| HK1203513A1 (en) | Methods of preparing substituted nucleotide analogs | |
| HK1203075A1 (en) | Substituted phosphorothioate nucleotide analogs | |
| BR112014007781A2 (pt) | compostos anti-virais | |
| CO6930353A2 (es) | Método para utilizar trazadores de liberación controlada | |
| BR112014015681A2 (pt) | análogos de glucagon | |
| BR112014007782A2 (pt) | compostos para transdução viral aperfeiçoada | |
| BR112014005087A2 (pt) | método para detectar nucleossomas contendo nucleotídeos | |
| JP2013527159A5 (ja) | イソフラボン抗ウイルス性化合物 | |
| JP2013525366A5 (ja) | ピリミジンジオン抗ウイルス性化合物 | |
| JP2013525368A5 (ja) | スルホンアミド抗ウイルス性化合物 | |
| BR112013024076A2 (pt) | análogos de glucagon | |
| ZA201309245B (en) | Novel fluoroergoline analogs | |
| GB201119390D0 (en) | Novel methods for determining nucleotide sequence repeats | |
| CO6842021A2 (es) | Análogos de ácido epoxieicosatrienoico y métodos para elaborarlosy utilizarlos | |
| GB201118636D0 (en) | Nucleotide sequence | |
| HK1199454A1 (en) | Antiviral compounds | |
| BR112014007599A2 (pt) | compostos anti-virais | |
| IT1403824B1 (it) | Fanale per autoveicoli | |
| BR112013030248A2 (pt) | aeronave | |
| EP2970366A4 (en) | NUCLEOTIDE ANALOG FOR SEQUENCING | |
| EP2699241A4 (en) | ANTIVIRAL COMPOUNDS | |
| BR112014008729A2 (pt) | processo para preparar ditiina-tetracarboximidas | |
| DE112012002210A5 (de) | Drucksystem |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Application granted |